



Kerydin® (tavaborole) – First-time generic

- On October 15, 2020, Encube Ethicals launched an [AB-rated](#) generic version of Pfizer's [Kerydin \(tavaborole\)](#) 5% topical solution.
 - On October 13, 2020, Perrigo received FDA approval of an [AB-rated](#) generic version of Kerydin. Launch plans are pending.
 - On October 21, 2020, Aleor Dermaceuticals received FDA approval of an [AB-rated](#) generic version of Kerydin. Launch plans are pending.
- Kerydin is approved for the treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.